Phase 1/2a CHMI clinical trial – Multivalent ChAd63/MVA

Objectives

The purpose of this study is to determine if combining partially effective vaccine approaches, primarily targeting induction of pre-erythrocytic cell-mediated immune responses to CSP, ME-TRAP and apical membrane antigen 1 (AMA1), increases the levels of protective efficacy in CHMI studies.

The vaccine approach is being tested in two clinical studies in which volunteers are immunized against a single antigen or a combination of two or three antigens. Priming doses are delivered using ChAd63 viral vector and boosting doses are delivered using MVA viral vector.

This project was developed in conjunction with the following project (multivalent pDNA/adenovirus) so that the results of the trials (using the same antigens but different platforms) can be considered together.